Wall Street Trader schreef op 2 november 2019 17:31:
Form SC 13D/A Gilead Sciences Inc
[Amend] General statement of acquisition of beneficial ownershipBased on 61,953,831 ordinary shares, no par value, of Galapagos NV (the “Issuer”) issued and outstanding as of October 25, 2019, as reported in the Issuer’s Form 6-K filed with the U.S. Securities and Exchange Commission on October 28, 2019 (the “October 28 Form 6-K”), plus the 7,039,243 ordinary shares, no par value, of the Issuer that are issuable to Gilead Therapeutics A1 Unlimited Company pursuant to the warrants described in this Schedule 13D/A based on the number of ordinary shares issued and outstanding as of October 25, 2019, as reported in the October 28 Form 6-K.
Shares Held Directly 20,628,929Percentage of Class 29.9sec.report/Document/0001104659-19-059...